5-(4-tert-butylphenoxy)-2,4-diaminoquinazoline | 215925-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-(4-tert-butylphenoxy)-2,4-diaminoquinazoline
• 英文别名: 5-(4-Tert-butylphenoxy)quinazoline-2,4-diamine
• CAS: 215925-69-2
• 化学式: C₁₈H₂₀N₄O
• 分子量: 308.383
• InChiKey: LEMFKFURBAGJBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS
  申请人：Zuo Jianping

  公开号：US20130261139A1

  公开（公告）日：2013-10-03

  Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.

  本发明揭示了一种使用式I的喹唑啉化合物，其中2,4-二氨基喹唑啉作为母核，用于制备治疗由黄病毒科感染引起的疾病的药物，特别是用于对抗丙型肝炎病毒感染和登革热病毒感染的用途。
• Formulations for hydrophobic pharmaceutical agents
  申请人：——

  公开号：US20010012844A1

  公开（公告）日：2001-08-09

  The present invention features formulations, including liquid, semi-solid or solid pharmaceutical formulations, that improve the oral bioavailability of hydrophobic pharmaceutical agents, such as quinazoline-, nitrothiazole-, and indolinone-based compounds. Also featured are formulations for parenteral delivery of such hydrophobic pharmaceutical agents, as well as methods of making and using both types of formulations.

  本发明涉及包括液体、半固体或固体制剂的配方，可以提高疏水性药物，如喹唑啉、硝基噻唑和吲哚酮类化合物的口服生物利用度。还包括适用于静脉注射递送这些疏水性药物的配方，以及制备和使用这两种类型配方的方法。
• Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
  申请人：——

  公开号：US20010014679A1

  公开（公告）日：2001-08-16

  The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.

  本发明部分涉及使用基于喹唑啉的化合物调节丝氨酸/苏氨酸蛋白激酶功能的方法。该方法包括表达丝氨酸/苏氨酸蛋白激酶（例如RAF）的细胞。此外，本发明还描述了使用本发明所确定的化合物预防和治疗有关丝氨酸/苏氨酸蛋白激酶的异常情况的方法。此外，本发明还涉及喹唑啉化合物和包含这些化合物的制药组合物。
• USE OF QUINAZOLINE COMPOUND IN PREPARATION OF ANTI-FLAVIVIRUS DRUG
  申请人：Shanghai Institute Materia Medica, Chinese Academy Of Sciences

  公开号：EP2649999A1

  公开（公告）日：2013-10-16

  Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.

  本发明公开了以 2,4-二氨基喹唑啉为母核的式 I 喹唑啉化合物在制备治疗由黄病毒感染引起的疾病的药物中的用途，特别是在防治丙型肝炎病毒感染和登革热病毒感染中的用途。
• METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS
  申请人：Sugen, Inc.

  公开号：EP0981519A1

  公开（公告）日：2000-03-01